Más de 600 artículos en profundidad sobre la terapia con iones pesados, la inmunoterapia y la medicina de precisión en Japón: manténgase al día sobre la atención médica internacional y la medicina regenerativa.
Fucoidan is a polysaccharide found in brown seaweed and sold as a food or supplement. This article explains what it is, what laboratory and human studies have looked at, and what to discuss with your doctor.
An overview of what cell, animal and human studies have observed about fucoidan, the limits of the current evidence, and what to talk over with your doctor before using it.
A gentle overview of everyday habits that support the immune system, and what research currently says, and does not say, about fucoidan as a food.
Fucoidan has been studied in relation to the immune system, allergies and skin. This article explains what the research has looked at, why the evidence is still limited, and how to think about it as a food.
Polysaccharides are found in vegetables, mushrooms and seaweed. This article explains what studies have observed about fucoidan and similar polysaccharides, the limits of the evidence, and what to discuss with your doctor about nutrition during treatment.
Hiroi Clinic is located in Koshienguchi, Nishinomiya, Hyogo. This page summarizes clinic information, consultation topics and how Medical Supporter coordinates with the clinic.
Hiroi Clinic is located in Koshienguchi, Nishinomiya, Hyogo. This page summarizes clinic information, consultation topics and how Medical Supporter coordinates with the clinic.
Dendritic cells (DCs), named from their initial two English letters, are a critical component of immunotherapy and function as the primary 'police' of the human immune system....
![[Lung Cancer Advanced Treatment] Leptomeningeal Metastases: What the BLOOM Trial Reported on Osimertinib and Intracranial Control](/images/blog/lunghtagrisso-0.webp?dpl=dpl_6Ch8SmBash6m4Nt3yx7kNpTWHJYF)
A literature summary of the BLOOM trial's design and primary endpoints for Osimertinib in EGFR-mutant non-small-cell lung cancer with leptomeningeal metastases. This article is not treatment advice; any medication decision must be evaluated by your treating oncologist.
之前我們寫了一篇關於日本免疫治療的趨勢後，有幾位跟我們聯繫，是否能夠更加詳盡的介紹樹突細胞。從免疫檢查哨抑制劑（Nivolumab等）的開發以及機制中能夠發現，CTL這種特殊的T淋巴球是相當重要的。因此藉由樹突細胞疫苗讓CTL增加，是對於癌症治療的方法之一。另外，單單的樹突細胞疫苗必須要認識癌細胞才能給予CTL指令，我
The FDA has approved a new breast cancer drug by Celcuity, but rollout concerns remain. Here is what international patients considering Japan should understand before acting.
Eli Lilly Japan has launched a new liquid suspension form of baricitinib (Ormient). Here's what it means for patients considering treatment in Japan.
The FDA has granted its first approval for a wearable on-body injectable anticancer device. Here's what cancer patients considering treatment abroad should know.
A plain-language summary of recent pembrolizumab-related developments—FDA review of a new combination, next-gen competitors, and biosimilar program changes—and what international patients should consider next.
The FDA has approved Celcuity's first breast cancer drug. Here's what this US regulatory milestone may — and may not — mean for patients exploring treatment options in Japan.
A new digital system connecting hospital documentation and insurance in Japan — what it means for patients considering cancer care at major Japanese centers.
The EU has approved Enhertu for previously treated HER2-positive metastatic solid tumours — the first tumour-agnostic HER2-directed antibody drug conjugate approval. Here's what it means for patients considering treatment options.
The FDA has approved ropeginterferon alfa-2b-njft (BESREMi Pen™) for polycythemia vera in the U.S. Here's what patients considering overseas treatment should know.
Lupin has received a US FDA tentative approval for a prostate cancer drug — what this regulatory step means, and what patients considering treatment in Japan should know.
The FDA has approved Aprepitant Injectable Emulsion by Azurity Pharmaceuticals. Here is what cancer patients considering treatment in Japan should know.
Ferring Pharma's Adstiladrin intravesical solution, a gene therapy for BCG-unresponsive bladder cancer, has received regulatory approval in Japan — here's what it means for patients considering treatment abroad.
Elevar Therapeutics CEO expects an FDA decision on a first-line liver cancer drug around July 23, 2026, with no outstanding review issues — what this may mean for patients exploring treatment options.
The FDA has approved new oncology drugs, imaging agents, and diagnostics. Here is what it means for patients considering treatment in Japan.
GSK's momelotinib has received Orphan Drug Designations in both the US and EU for VEXAS syndrome — a regulatory milestone, not yet a treatment approval. Here's what it means for patients.
The FDA has approved a Guardant Health companion diagnostic to help identify eligible patients for a new Boehringer Ingelheim cancer drug. Here's what it means for patients exploring treatment options.
Sawai Pharmaceutical announced expanded indications and dosage approval for Lenalidomide Capsules in Japan — here is what it may mean for patients considering treatment there.
One of Japan's cancer hospitals has partnered with J&J to advance clinical trials — here's what it may mean for patients considering treatment in Japan.
Replimune has been given a third opportunity to seek US approval for a skin cancer drug. Here's what this regulatory development means for patients considering treatment in Japan.
RadioMedix has received U.S. FDA approval for a generic Ga-68 PSMA-11 imaging agent for prostate cancer. Here's what it means for patients considering care abroad.
Merck's Welireg and Keytruda combination has received regulatory approval for kidney cancer patients following surgery. Here's what it means if you're exploring treatment options.
Fucoidan is a polysaccharide found in brown seaweed and sold as a food or supplement. This article explains what it is, what laboratory and human studies have looked at, and what to discuss with your doctor.
An overview of what cell, animal and human studies have observed about fucoidan, the limits of the current evidence, and what to talk over with your doctor before using it.
A gentle overview of everyday habits that support the immune system, and what research currently says, and does not say, about fucoidan as a food.
Fucoidan has been studied in relation to the immune system, allergies and skin. This article explains what the research has looked at, why the evidence is still limited, and how to think about it as a food.
Polysaccharides are found in vegetables, mushrooms and seaweed. This article explains what studies have observed about fucoidan and similar polysaccharides, the limits of the evidence, and what to discuss with your doctor about nutrition during treatment.
Hiroi Clinic is located in Koshienguchi, Nishinomiya, Hyogo. This page summarizes clinic information, consultation topics and how Medical Supporter coordinates with the clinic.
Hiroi Clinic is located in Koshienguchi, Nishinomiya, Hyogo. This page summarizes clinic information, consultation topics and how Medical Supporter coordinates with the clinic.
Dendritic cells (DCs), named from their initial two English letters, are a critical component of immunotherapy and function as the primary 'police' of the human immune system....
A literature summary of the BLOOM trial's design and primary endpoints for Osimertinib in EGFR-mutant non-small-cell lung cancer with leptomeningeal metastases. This article is not treatment advice; any medication decision must be evaluated by your treating oncologist.
之前我們寫了一篇關於日本免疫治療的趨勢後，有幾位跟我們聯繫，是否能夠更加詳盡的介紹樹突細胞。從免疫檢查哨抑制劑（Nivolumab等）的開發以及機制中能夠發現，CTL這種特殊的T淋巴球是相當重要的。因此藉由樹突細胞疫苗讓CTL增加，是對於癌症治療的方法之一。另外，單單的樹突細胞疫苗必須要認識癌細胞才能給予CTL指令，我
The FDA has approved a new breast cancer drug by Celcuity, but rollout concerns remain. Here is what international patients considering Japan should understand before acting.
Eli Lilly Japan has launched a new liquid suspension form of baricitinib (Ormient). Here's what it means for patients considering treatment in Japan.
The FDA has granted its first approval for a wearable on-body injectable anticancer device. Here's what cancer patients considering treatment abroad should know.
A plain-language summary of recent pembrolizumab-related developments—FDA review of a new combination, next-gen competitors, and biosimilar program changes—and what international patients should consider next.
The FDA has approved Celcuity's first breast cancer drug. Here's what this US regulatory milestone may — and may not — mean for patients exploring treatment options in Japan.
A new digital system connecting hospital documentation and insurance in Japan — what it means for patients considering cancer care at major Japanese centers.
The EU has approved Enhertu for previously treated HER2-positive metastatic solid tumours — the first tumour-agnostic HER2-directed antibody drug conjugate approval. Here's what it means for patients considering treatment options.
The FDA has approved ropeginterferon alfa-2b-njft (BESREMi Pen™) for polycythemia vera in the U.S. Here's what patients considering overseas treatment should know.
Lupin has received a US FDA tentative approval for a prostate cancer drug — what this regulatory step means, and what patients considering treatment in Japan should know.
The FDA has approved Aprepitant Injectable Emulsion by Azurity Pharmaceuticals. Here is what cancer patients considering treatment in Japan should know.
Ferring Pharma's Adstiladrin intravesical solution, a gene therapy for BCG-unresponsive bladder cancer, has received regulatory approval in Japan — here's what it means for patients considering treatment abroad.
Elevar Therapeutics CEO expects an FDA decision on a first-line liver cancer drug around July 23, 2026, with no outstanding review issues — what this may mean for patients exploring treatment options.
The FDA has approved new oncology drugs, imaging agents, and diagnostics. Here is what it means for patients considering treatment in Japan.
GSK's momelotinib has received Orphan Drug Designations in both the US and EU for VEXAS syndrome — a regulatory milestone, not yet a treatment approval. Here's what it means for patients.
The FDA has approved a Guardant Health companion diagnostic to help identify eligible patients for a new Boehringer Ingelheim cancer drug. Here's what it means for patients exploring treatment options.
Sawai Pharmaceutical announced expanded indications and dosage approval for Lenalidomide Capsules in Japan — here is what it may mean for patients considering treatment there.
One of Japan's cancer hospitals has partnered with J&J to advance clinical trials — here's what it may mean for patients considering treatment in Japan.
Replimune has been given a third opportunity to seek US approval for a skin cancer drug. Here's what this regulatory development means for patients considering treatment in Japan.
RadioMedix has received U.S. FDA approval for a generic Ga-68 PSMA-11 imaging agent for prostate cancer. Here's what it means for patients considering care abroad.
Merck's Welireg and Keytruda combination has received regulatory approval for kidney cancer patients following surgery. Here's what it means if you're exploring treatment options.